@article{abc86eeed82f425ca94ca5499112080e,
title = "Aβ imaging: Feasible, pertinent, and vital to progress in Alzheimer's disease",
author = "Villemagne, \{Victor L.\} and Klunk, \{William E.\} and Mathis, \{Chester A.\} and Rowe, \{Christopher C.\} and Brooks, \{David J.\} and Hyman, \{Bradley T.\} and Ikonomovic, \{Milos D.\} and Kenji Ishii and Jack, \{Clifford R.\} and Jagust, \{William J.\} and Johnson, \{Keith A.\} and Koeppe, \{Robert A.\} and Lowe, \{Val J.\} and Masters, \{Colin L.\} and Montine, \{Thomas J.\} and Morris, \{John C.\} and Agneta Nordberg and Petersen, \{Ronald C.\} and Reiman, \{Eric M.\} and Selkoe, \{Dennis J.\} and Sperling, \{Reisa A.\} and \{Van Laere\}, Koen and Weiner, \{Michael W.\} and Alexander Drzezga",
note = "Funding Information: Conflicts of interest This response represents a consensus opinion of all coauthors, is meant to apply to all current amyloid PET tracers equally, and is not meant to favor any one particular tracer over any other. Two coauthors (WEK and CAM) have a conflict of interest based on being coinventors of an amyloid imaging tracer licensed by GE Healthcare, several coauthors (AD, MDI, KI, WJJ, KAJ, WEK, VJL, CLM, CAM, AN, RCP, EMR, CCR, RAS, KVL, VLV, and MWW) have been paid consultants to or received research grant support from one or more of the companies developing commercial amyloid imaging tracers (AstraZeneca, Bayer Schering, GE Healthcare Merck and/or Avid/Lilly) and one coauthor (DJB) holds a part-time position as a Senior Neurologist with GE Healthcare. Six coauthors have no conflicts of interest relative to amyloid PET tracers (BTH, CRJ, RAK, TJM, JCM, DJS).",
year = "2012",
month = feb,
doi = "10.1007/s00259-011-2045-0",
language = "English",
volume = "39",
pages = "209--219",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
number = "2",
}